Abstract 6498: CRISPRi Screening Identifies PIAS4 as a Regulator of NRF2-Associated Stress Adaptation in Heart Failure Failure
Abstract
Background: Activation of the DNA damage response (DDR) contributes to cardiac dysfunction through the p53/p21 pathway, yet the molecular mechanisms governing DDR adaptation in terminally differentiated cardiomyocytes remain incompletely understood. We aimed to identify key regulators of cardiac DDR and stress adaptation using a CRISPR interference (CRISPRi)-based screening platform and to uncover novel therapeutic targets for heart failure. Methods: A human induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) expressing dCas9-KRAB was established for arrayed CRISPRi screening. A total of 437 DDR-related genes were individually silenced and evaluated under H 2 O 2 -induced oxidative stress. DDR activation was quantified by high-content imaging of γH2AX and p21 expression. Candidate genes were further investigated using loss- and gain-of-function approaches, transcriptomic analysis, metabolic assays, and molecular studies. Therapeutic relevance was assessed by myo-AAV mediated Pias4 overexpression and treatment with BC1485, a small-molecule reported to stabilize of PIAS4, in a transverse aortic constriction (TAC) model. Single-cell RNA sequencing was performed on TAC hearts. Results: By CRISPRi screening, Protein Inhibitor of Activated STAT4 (PIAS4) emerged as one of protective regulator, as its depletion enhanced oxidative stress-induced DDR-marker accumulation. PIAS4 knockdown enhanced γH2AX and p21 expression following oxidative stress, indicating increased DDR activation. Transcriptomic analysis revealed downregulation of mitochondrial-associated gene programs, while metabolic analysis demonstrated impaired mitochondrial respiration. In contrast, PIAS4 overexpression suppressed oxidative stress-induced DDR activation. myo-AAV mediated Pias4 overexpression attenuated TAC-induced left ventricular dysfunction and reduced myocardial DNA damage in vivo. Single-cell RNA sequencing analysis demonstrated selective activation of Nrf2-associated antioxidant transcriptional programs in Pias4 -overexpressing cardiomyocytes, including pathways involved in redox homeostasis and cellular stress adaptation. Mechanistically, PIAS4 overexpression increased SUMOylated NRF2 species and was accompanied by enhanced NRF2 nuclear accumulation without altering NFE2L2 (NRF2) mRNA expression level. PIAS4 also increased the expression of antioxidant target genes, including SOD1, NQO1, HMOX2 , and FTH1 , thereby suppressing oxidative stress and DNA damage. Furthermore, pharmacological stabilization of PIAS4 using BC1485 reduced DDR activation in vitro and improved cardiac function in TAC mice. Conclusions: PIAS4 is a critical regulator of cardiomyocyte stress adaptation that enhances antioxidant gene expression through NRF2 SUMOylation. These findings nominate PIAS4-NRF2 pathway as a therapeutic target for heart failure.